Scholarlink

Background <p>This study investigated the therapeutic potential of exosomes derived from human umbilical cord mesenchymal stem cells (hUCMSCs-exos) in an Ovalbumin (OVA) -induced mouse model of allergic asthma, comparing their efficacy to budesonide, a standard asthma treatment. hUCMSCs-exos were characterized by their typical morphology, size, and marker expression (CD9, CD63, and HSP70) using transmission electron microscopy (TEM), Nanosight 300, and Western blot analysis.</p> Results <p>Treatment with hUCMSCs-exos significantly decreased lung inflammation by detecting plasma IL-4 and IgE levels, as well as white blood cells and eosinophils counts in Bronchoalveolar lavage fluid (BALF), the M1 and M2 type of macrophages, Regulatory T Cells (Tregs) in lung tissues, paralleling the effects of budesonide therapy. Notably, hUCMSCs -exos achieved a greater reduction in the percentage of eosinophils in BALF and a significant increase M2 macrophages and Tregs in lung tissues.</p> Conclusions <p>These findings suggest hUCMSCs-exos may offer comparable or superior therapeutic benefits to budesonide, warranting further investigation into their molecular mechanisms to support clinical application.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Application of exosomes derived from human umbilical cord stem cells in the treatment of ovalbumin-induced allergic asthma in mice

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月18日

查看全文
  • Yong Ding,
  • Yanli Zhang,
  • Qi Cao,
  • Yong Yin,
  • Zhenglai Ma,
  • Wenxia Pan,
  • Xinjie Du,
  • Chunling Ma

摘要

Background

This study investigated the therapeutic potential of exosomes derived from human umbilical cord mesenchymal stem cells (hUCMSCs-exos) in an Ovalbumin (OVA) -induced mouse model of allergic asthma, comparing their efficacy to budesonide, a standard asthma treatment. hUCMSCs-exos were characterized by their typical morphology, size, and marker expression (CD9, CD63, and HSP70) using transmission electron microscopy (TEM), Nanosight 300, and Western blot analysis.

Results

Treatment with hUCMSCs-exos significantly decreased lung inflammation by detecting plasma IL-4 and IgE levels, as well as white blood cells and eosinophils counts in Bronchoalveolar lavage fluid (BALF), the M1 and M2 type of macrophages, Regulatory T Cells (Tregs) in lung tissues, paralleling the effects of budesonide therapy. Notably, hUCMSCs -exos achieved a greater reduction in the percentage of eosinophils in BALF and a significant increase M2 macrophages and Tregs in lung tissues.

Conclusions

These findings suggest hUCMSCs-exos may offer comparable or superior therapeutic benefits to budesonide, warranting further investigation into their molecular mechanisms to support clinical application.